UK First: Manchester Hospital Delivers Groundbreaking CAR-T Cell Therapy for Aggressive Blood Cancer

In a clinical breakthrough that's being called a watershed moment for cancer treatment in the UK, Manchester Royal Infirmary has successfully delivered the first NHS treatment using a next-generation CAR-T cell therapy for patients with aggressive T-cell malignancies. CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy that reprograms a patient's own immune cells to recognize and destroy cancer. While CAR-T therapies have transformed treatment for certain blood cancers in recent years, this new therapy targets T-cell cancers—a particularly aggressive and difficult-to-treat group of malignancies. 'This is an incredibly exciting moment for our patients and our team,' said Professor John Gribben, lead haematologist at Manchester Royal Infirmary. 'For patients with relapsed or refractory T-cell lymphomas, treatment options have been extremely limited. This therapy offers real hope where there was little before.' The therapy works by extracting T-cells from the patient's blood, genetically engineering them in a specialized laboratory to attack cancer cells, then reinfusing them back into the patient. The modified cells multiply and hunt down cancer throughout the body. What makes this therapy particularly remarkable is that it uses CRISPR gene-editing to prevent the CAR-T cells from attacking each other—a problem that has historically made T-cell targeted therapies extremely challenging to develop. The FDA granted the therapy Breakthrough Therapy Designation in January 2026, recognizing its potential to significantly improve treatment for a serious condition. The first NHS patient to receive the therapy is responding well, with early monitoring showing positive results. 'Being able to offer this cutting-edge treatment through the NHS means patients across the UK will have access to potentially life-saving therapy regardless of their ability to pay,' added Professor Gribben. 'That's what the NHS is all about.' The success opens the door for expanded trials and potential approval for wider use across the UK and Europe.